Stock 4013 DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Financials Dr. Sulaiman Al Habib Medical Services Group Company

Equities

4013

SA1510P1UMH1

Healthcare Facilities & Services

End-of-day quote Saudi Arabian S.E.
Other stock markets
 03:30:00 02/05/2024 am IST 		5-day change 1st Jan Change
311.6 SAR +0.19% Intraday chart for Dr. Sulaiman Al Habib Medical Services Group Company -1.08% +9.72%
28/04 Dr. Sulaiman Al Habib Medical Services Group Company Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
28/04 Dr. Sulaiman Al Habib Medical Services Logs Increase in Q1 Profit, Revenue MT

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 38,150 56,490 77,210 99,400 1,09,060 - -
Enterprise Value (EV) 1 38,150 56,609 77,663 1,01,963 1,14,903 1,14,976 1,16,176
P/E ratio 36.1 x 41.1 x 46.7 x 48.5 x 49.1 x 39.7 x 33.5 x
Yield 1.38% 1.67% - - 1.3% 1.7% 1.73%
Capitalization / Revenue 6.51 x 7.79 x 9.29 x 10.5 x 9.68 x 7.34 x 6.72 x
EV / Revenue 6.51 x 7.81 x 9.34 x 10.7 x 10.2 x 7.74 x 7.16 x
EV / EBITDA 26.6 x 31.8 x 38.6 x 42.3 x 38.8 x 32 x 27.5 x
EV / FCF 26.9 x 60.9 x 58.4 x -403 x 461 x 62.6 x 44.6 x
FCF Yield 3.72% 1.64% 1.71% -0.25% 0.22% 1.6% 2.24%
Price to Book 7.77 x 10.6 x 13.1 x 15.3 x 15.1 x 13.5 x 11.5 x
Nbr of stocks (in thousands) 3,50,000 3,50,000 3,50,000 3,50,000 3,50,000 - -
Reference price 2 109.0 161.4 220.6 284.0 311.6 311.6 311.6
Announcement Date 21/02/21 20/02/22 21/02/23 20/02/24 - - -
1SAR in Million2SAR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 5,862 7,250 8,311 9,508 11,267 14,857 16,219
EBITDA 1 1,433 1,781 2,010 2,408 2,963 3,593 4,231
EBIT 1 1,115 1,466 1,700 2,096 2,371 3,007 3,566
Operating Margin 19.02% 20.22% 20.46% 22.04% 21.04% 20.24% 21.99%
Earnings before Tax (EBT) 1 1,128 1,491 1,797 2,170 2,404 3,057 3,729
Net income 1 1,055 1,377 1,651 2,046 2,212 2,813 3,293
Net margin 18.01% 18.99% 19.86% 21.52% 19.63% 18.94% 20.31%
EPS 2 3.020 3.930 4.720 5.850 6.340 7.849 9.293
Free Cash Flow 1 1,420 929.3 1,330 -252.7 249.5 1,836 2,604
FCF margin 24.23% 12.82% 16.01% -2.66% 2.21% 12.36% 16.05%
FCF Conversion (EBITDA) 99.14% 52.18% 66.19% - 8.42% 51.1% 61.54%
FCF Conversion (Net income) 134.57% 67.5% 80.59% - 11.28% 65.26% 79.05%
Dividend per Share 2 1.500 2.700 - - 4.060 5.302 5.397
Announcement Date 21/02/21 20/02/22 21/02/23 20/02/24 - - -
1SAR in Million2SAR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1
Net sales 1 1,968 1,991 2,014 2,052 2,254 2,307 2,272 2,443 2,486 2,521
EBITDA - 498.7 - - 505.3 - 577 - - -
EBIT 1 396.3 422.1 414.7 436.1 427.6 510.6 498.8 552.1 534.2 556.1
Operating Margin 20.13% 21.2% 20.59% 21.25% 18.97% 22.13% 21.95% 22.6% 21.48% 22.05%
Earnings before Tax (EBT) - - - - - - - - - -
Net income 1 383.6 390.5 398.1 420.6 441.5 489.3 487 544.8 491 551
Net margin 19.49% 19.61% 19.77% 20.5% 19.59% 21.21% 21.43% 22.3% 19.75% 21.85%
EPS 2 1.090 - - 1.200 1.260 1.400 1.390 1.560 1.500 1.570
Dividend per Share - - - - - - - - - -
Announcement Date 20/02/22 24/04/22 07/08/22 23/10/22 21/02/23 07/05/23 06/08/23 30/10/23 20/02/24 28/04/24
1SAR in Million2SAR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 119 453 2,563 5,843 5,916 7,116
Net Cash position 1 - - - - - - -
Leverage (Debt/EBITDA) - 0.0667 x 0.2255 x 1.064 x 1.972 x 1.646 x 1.682 x
Free Cash Flow 1 1,420 929 1,330 -253 250 1,836 2,604
ROE (net income / shareholders' equity) 22.7% 26.9% 29.4% 33.1% 32.1% 35.7% 37%
ROA (Net income/ Total Assets) 11.8% 13.6% 14.1% 14.4% 12.8% 16% 15%
Assets 1 8,974 10,154 11,706 14,191 17,282 17,611 22,030
Book Value Per Share 2 14.00 15.30 16.80 18.50 20.60 23.10 27.00
Cash Flow per Share 2 - - - 9.270 7.200 8.700 11.10
Capex 1 758 1,254 1,513 3,497 4,022 2,148 1,728
Capex / Sales 12.93% 17.29% 18.21% 36.78% 35.7% 14.46% 10.65%
Announcement Date 21/02/21 20/02/22 21/02/23 20/02/24 - - -
1SAR in Million2SAR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Dr. Sulaiman Al Habib Medical Services Group Company

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
311.6 SAR
Average target price
290.3 SAR
Spread / Average Target
-6.83%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

1st Jan change Capi.
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
+9.72% 29.08B
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+13.70% 80.61B
CVS HEALTH CORPORATION Stock CVS Health Corporation
-29.20% 70.18B
LABORATORY CORPORATION OF AMERICA HOLDINGS Stock Laboratory Corporation of America Holdings
-11.43% 16.97B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
-0.43% 16.96B
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
-0.31% 15.26B
FRESENIUS MEDICAL CARE AG Stock Fresenius Medical Care AG
+3.42% 12.41B
PURE HEALTH HOLDING Stock Pure Health Holding
-30.70% 11.95B
REDE D'OR SÃO LUIZ S.A. Stock Rede D'Or São Luiz S.A.
-6.75% 11.93B
NATERA, INC. Stock Natera, Inc.
+54.82% 11.85B
Other Healthcare Facilities & Services
  1. Stock Market
  2. Equities
  3. 4013 Stock
  4. Financials Dr. Sulaiman Al Habib Medical Services Group Company